A study by Witt et al., using a mouse model of PCa, reported that signal transducer and activator of transcription 3 (STAT3) inhibition by GPB730 enhances the antitumor efficacy and activity of anti-CTLA-4, along with decreasing intratumoral Treg frequency, supporting the combination of STAT3 inhibition with anti-CTLA-4 therapy [44]. This evidence concerns the gene STAT3 and posterior cortical atrophy.